ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[The role of AKT inhibitors combined with Ruxolitinib in ameliorating myeloproliferative disorders in mice with CALR gene mutations].
L W Zhang, Q G Zhang, M C Ji, K M Qi, Z Y Li, K L Xu, C L Fu
Abstract readEnglish Abstract
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
L W ZhangDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
Q G ZhangDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
M C JiDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
K M QiDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
Z Y LiDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
K L XuDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
C L FuDepartment of Hematology, Institute of Hematology, Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China.
Funding
Basic Science (Natural Science) in Provincial Universities 23KJA320008Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit JSDW202213
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
CalreticulinHeterocyclic Compounds, 3-RingMyeloproliferative DisordersProto-Oncogene Proteins c-aktPyrazolesAnimalsDisease Models, AnimalFemaleMiceMice, Inbred C57BLMutationNitrilesPyrimidinesCalreticulinHeterocyclic Compounds, 3-RingMK 2206NitrilesProto-Oncogene Proteins c-aktPyrazolesPyrimidinesruxolitinibAKT inhibitorCALRMyeloproliferative tumorRuxolitinib
Identifiers
PMID41087184
PMCPMC12541485
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390